JWHolding

2020

- Obtainment of a US patent for an early diagnosis technology of pancreatic cancer
- Joint development of a next-generation nutrient sap with Baxter
- Conclusion of the Winuf® exclusive technology exportation and provision agreement with Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. in China

2019

- C&C Research Laboratories, JW Pharmaceutical Subsidiary transfer
- Signed a technology export contract with the Simcere company in China, 'URC102' for gout treatment
- Acquired 'Euvipharm', the first Vietnamese pharmaceutical company in Korea
- Atopic dermatitis ‘JW1601’ won the ‘Technology Exporter’ and the 'King Sejong the Great', the highest patented technology in Korea
- Acquired patents for China and Europe for early diagnosis of pancreatic cancer
- A hemophilia drug 'hemri Bra' rare drug designation and market sales permit
- Asia’s first sell a three-chamber nutrient infusion in EU

2018

J- W Life Science Industry First "Nutrient Toolking" in Asia Get EU – GMP
- Technology export of atopic dermatitis drug 'JW1601'

2017

- 2017 Signed export contract for ‘Ertapenem’, the next generation antibiotic with Gland Pharma from India

2016

- JW Lifescience listed on Securities Market

2015

- Vision 70+5 Declaration

2013

- Signed Export Agreement with America’s Baxter for - 3-Chamber Nourishment Transfusion Fluid Joint-Development - agreement with Japan’s SKK worth 100 billion for - pharmaceutical products Founded True Medical Personnel - respecting life, enacted ‘Sungcheon Award’

2012

- CRelocation of C&C new medicine research institute - (DRC hall, Sungkyunkwan University, Suwon natural science campus)

2011

- Renamed to JW Holdings Corporation
- Renamed to JW Pharmaceutical Corporation
- Renamed to JW Shinyak Corporation
- Renamed to JW Life Science Corporation
- Renamed to JW Medical Corporation
- Renamed to JW Living Healthcare Corporation

2010

- JW Dangjin Production Complex, which is Korea’s largest
- Medicine-manufacturing plant, was built

2009

- JW Shinyak was listed on the KOSDAQ Awarded
- US$30 mil-Export Tower

2008

- Took over Three-Seven Certified as Good Labor Culture Enterprise from Labor Ministry Eco-friendly B1 established

2007

- Awarded Presidential Citation on the occasion of Environment
- Day Choongwae Holdings established

2006

- World’s largest Non-PVC supplement plant (Dangjin) was built

2005

- Designated as Korea’s 30-respectable enterprises(Dong-A Ilbo Daily, IBM BCS)
- Designated as Asia’s 200 outstanding enterprises (Fobes Asia)
- Choongwae Shinyak established

2004

- Antibiotics, ‘Impenem’ first generic with US$600 mil-scale - potential Global market developed Impenem plant meeting - EU GMP standard was built (Sihwa)

2003

- Awarded the 3rd Gyeonggi Green Environment Trophy  - (Gyeonggi Province)
- Awarded the 4th Korea Business Image Grand Prize by KMAC
- Awarded the 5th Industrial Peace Grand Prize

2002

- Awarded New Medicine Development Prize with Balofloxacin (Ginko biloba leaf extract)
- Antibiotics Ketoconnazole was certified by Europe COS

JW has started its steps with the restoration of nation’s independence

JW’s footstep which has brought about the great accomplishment Represents the history of Korea’s pharmaceutical industry.

2001

Awarded the 1st CEO grand prize (Korea CEO Academy)
Balofloxacin certified by KFDA as Phase Ⅲ shinyak for the first time in Korea

2000

Awarded US$10mil Export Tower Theriac Research
Corporation established (Joint research agreement with PNRI)

1999

Hydration solution production exceeded 1 billion bottles
Choongwae Information Technology (CIT) established

1998

Designated as Good Pharmaceutical company (Medical Paper, Ilgan Bosa)
Awarded the 5th Foundation Prize (KASBA)

1997

Designated as Good Labor-Management relationship company (Labor Ministry)
Antifungal Itraconazole developed

1995

Awarded the 4th Economy Righteousness Enterprise
Awarded Industrial Bronze Tower

1994

Designated as Good Environment Enterprise for 3 consecutive
Years Choongwae Chemcal established
Arthythima treatment medicine, KCB, developed

1993

JW Medical established by meeting Choongwae Machinery and Choongwae trading company

1992

C&C Research & Lab established

1991

Chungmo Pharmaceutical renamed to Daeyoo
Designated as eligible KGMP company (Health Ministry)

1990

Chungmo Pharmaceutical merged
Awarded Moran Medal

1988

Choongwae Industrial established

1997

Choongwae Medical Corp’s Yongin plan completed
Designated as KGMP eligible company (Health Ministry)
Awarded Moran Medal

JW has started its steps with the restoration of nation’s independence

JW’s footstep which has brought about the great accomplishment Represents the history of Korea’s pharmaceutical industry.

1986

Head office moved to 698. Shindaebang-dong, Dongjaak-gu, Seoul

1984

Awarded Saemaeul Hyunpdong Medal

1983

General R&D institute established: Designated as subsidiary intitute By the Ministry of Science and Technology

1982

Renamed to Choongwae Pharmaceutical

1977

Factory built at 146-141, 
Annyung-ri, Taean-eup, Hwansung-gun, Gyeonggi province
Choongwae machinery established

1976

Initial Public Offering : 
capital 800 mil-Listed on the stock market

1975

JGMP-based manufacture and inspection record system established (for the first time in Korea)

1972

Daehan Choongwae Corp established

1969

Awarded Invention Prize (development of TC water soluble Derivative (Lymecycline HCL)

1953

Daehan Choongwae Medical Corp established

1945

Joseon Choongwae Pharmaceutical established (at 3-ga, Choongmuro, Seoul)